Navigation Links
IR BioSciences Announces Promising Data from Study of Its Compound,Homspera

Data Suggests Homspera Shows Promise As an Adjuvant for Vaccines against Avian Flu and Other Viruses

SCOTTSDALE, Ariz., May 07, 2007 /PRNewswire-FirstCall/ -- IR BioSciences Holdings, Inc. announced today that preliminary data from its influenza vaccine adjuvant study being performed in conjunction with GenPhar Inc. indicates Homspera elevates host immune responsiveness above that induced by vaccine alone system. These results are from an ongoing study, and are a strong indication that Homspera may demonstrate adjuvant capabilities, and thus be capable of augmenting host immune system responsiveness to vaccines for diseases such as pandemic avian influenza, seasonal influenza, and perhaps others for which vaccines exist or are under development.

Adjuvants are common additions to vaccine formulations, as they enable the vaccine to induce a strong immune reaction in vaccinated individuals, helping to ensure adequate immunological protection.

The Homspera studies, being carried out by GenPhar, examine the impact of vaccination with pieces of influenza viruses (a current H5N1 "avian influenza" strain and from the 1918 Spanish Influenza virus). A fear of many scientists and public health officials is that the current avian influenza endemic to Southeast Asia may mutate sufficiently to become more easily transmitted among humans, yet maintain its highly pathogenic nature. Such an event, centered on the virus currently exhibiting mortality in infected humans of approximately 50%, can trigger a rapid global spread of highly pathogenic virus with disastrous consequences.

Vaccines against avian influenza are not available in volumes needed to inoculate a significant percentage of the world's population. Similarly, the most effective prophylactic or therapeutic drug, oseltamivir (Tamiflu(R), Roche), is reportedly not being stockpiled in amounts adequate to provide protection to the at-risk population.
'"/>




Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
4. Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
5. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
6. ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent
7. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
8. IR BioSciences Announces Data Demonstrating Radilex Stimulation of Stem Cells Results in Hematopoietic Recovery Following Lethal Irradiation
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

Post Your Comments:
(Date:11/9/2009)... /PRNewswire/ -- On Sept. 11, 2001, thousands of...rkers came together to save as many lives as possi...Cauley was one of those 9/11 first responders. Now...n his late 30s, McCauley was diagnosed with cancer...hemotherapy treatments, leaving him confined to a ...
(Date:11/9/2009)...e/ -- AMD LASERS just announced that industry lead...pted the position of Medical Director. In his new...g research and development of new soft and hard ti...ontinuing education credits, authoring articles fo... lecturing and seminar engagements. ,, "We are ...
(Date:11/9/2009)...Newswire/ -- LifeNet Health, a leading allograft b...raft Cervical Bio-Implant (VG2C) with Preservon...prietary glycerol-based preservation solution that...ully hydrated state at ambient temperature. This e...lants, doing away with lengthy thawing and rehydra...
Breaking Medicine Technology:The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3AMD LASERS Names Dr. James Jesse as Medical Director 2LifeNet Health Announces First Bio-Implant with New Preservation Technology 2SXC Health Solutions to present at upcoming conferences 58075 1SXC Health Solutions to present at upcoming conferences 58075 2Study Suggests a Wider Use for Statins 58073 1Study Suggests a Wider Use for Statins 58073 2Study Suggests a Wider Use for Statins 58073 3Georgia State researcher to use 241 million grant to improve computer models for fighting wildfires 10045 1Georgia State researcher to use 241 million grant to improve computer models for fighting wildfires 10045 2
...mab Cancer Trial Is Evaluating the, Anti-Tumor A...atin and Paclitaxel --...als, Inc. (Nasdaq: PPHM ) today announced that pa... trial designed to evaluate the safety,and efficac...in patients,with non-small cell lung cancer (NSCLC...
...etics,(Nasdaq: DCGN ) today announced positive to...y study of DG041, the company,s first-in-class,ant...developed as a,next-generation oral anti-platelet ... increasing bleeding risk. The prospective, random... on platelet activation and,bleeding time of DG041...
Other Medicine Technology:Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 2DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 3DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin 4
(Date:11/9/2009)...tCall/ - Hard To Treat Diseases (HTDS.PK) www.htd...$41 billion international healthcare company, is a...r, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.,...begin a five-year, $1 billion China initiative wit... its investment in its China R&D facility, and...
(Date:11/9/2009)...late when it comes to preventing or improving a di...ke Off Pounds Sensibly), the nonprofit weight-loss...(Vocus) November 9, 2009 -- Tomorrow may be too la...etes condition, according to TOPS Club, Inc. (Take...upport organization., , ,Diabetes is a disease in ...
(Date:11/9/2009)... positive influence of sports participation on bon...Vocus) November 9, 2009 -- As people age fractures...ch has highlighted the importance of exercise and ...However, a new study published in the November/Dec... Approach reveals that there may be significant g...
(Date:11/9/2009).../ -- Actress Mariska Hargitay and the Joyful Hea...to raise awareness about the need for domestic vio...ilding healing and wellness kits for women in cris... to each of the estimated 600 women currently bein...iolence shelters. ,, "Our goal is to shine a li...
(Date:11/9/2009)...assador ,, WHITE PLAINS, N.Y., Nov. 9 /PRNews..., was born so early and with so many underdevelope...ld survive -- or if he would ever walk, talk, see ...Dimes 2010 National Ambassador. ,, Joshua,s mo...motherhood and I was completely devastated. My hus...
Breaking Medicine News(10 mins):Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 2Health News:Actress Mariska Hargitay and the Joyful Heart Foundation Join philosophy to Serve Women in Crisis Throughout Los Angeles County 3Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3
...to be a common condition among the senior lot in A...heir recovery process from an illness or accident...Sydneys Prince of Wales Hospital showed that almos...of stay in the hospital. Associate Profes...
...rough suppressing communication between the cells ...epsy and schizophrenia. Researchers at th...a protein that could do the trick. The SUMO protei...kling diseases such as epilepsy and schizophrenia,...
...utated with no recourse, injected stem cells could...g. Thus stem cells offer immense hope to scientis... patient. Now, scientists have explored th...mbryos, called hemangioblast cells are capable of ...
...the lesser of two evils or the better of two goods...d by just one name , is a severely disabled nine -...sability, mental disability as well renders her mi... whom they refer to as the pillow angel, on an onl...
...es not do any good to the human body, it is known.... lot may have higher blood pressure and heart rat...s hormones that strain the heart, more depression ...ally let go of things, shows a new study by psycho...
...nd psychology research both indicate that paying c...cing something else. However, a new study... that attention does not have a fixed capacity - a...psychology and psychiatry professor Richard Davids...
Other Medicine News:Health News:British Scientists Discover New Protein to Treat Epilepsy and Schizophrenia 2Health News:Human Rights Activists Sleepless In Seattle 2Health News:Brooding Could Kill, Warn Psychologists 2Health News:Meditation May Fine-Tune Control Over Attention 2
Calcitonin Assay Immunoradiometric (IRMA) Assay
...licular C-cells of the thyroid gland and is packag...itonin is to lower plasma calcium concentrations, ...creased mobilization of calcium from bone [1]. Thi...with high levels of bone remodeling (e.g. in Paget...
Calcitonin RIA Kit
...n Frequency Doubling Technology. It represents a s... combining early glaucoma detection capabilities, ...management tools., ,Like the Humphrey FDT Peri... screener with 35 second supra-threshold testing. ...
Medicine Products: